Business Wire

Audiencerate: Riccardo Fabbri Joins as Chief Technology Officer — The AI-Driven Phase of the Platforms for SMEs and Media Agencies Begins

21.5.2026 09:00:00 CEST | Business Wire | Press Release

Share

Audiencerate Ltd, one of the few globally certified Google Customer Match Upload Partners and a Microsoft IP Co-sell certified partner with MACC eligibility, today announced the appointment of Riccardo Fabbri as Chief Technology Officer. The appointment marks a phase of dual expansion: the Audiencerate–Postel–Microsoft platform for Italian SMEs, and the Data platform integrated with Google DV360 for Agencies and Data Providers — both evolving toward a model that natively leverages first-party and third-party data through AI and machine learning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519344995/en/

Riccardo Fabbri, Chief Technology Officer of Audiencerate Ltd. Co-founder and former managing partner of Nohup, recognized by the Financial Times among Europe's leading firms in the sector (2021 and 2022) and acquired by the Havas Group in August 2021. Leads the AI-driven phase of Audiencerate's independent Customer Match infrastructure.

A profile built on twenty years of digital transformation

Fabbri brings to Audiencerate over two decades of experience in software development and cloud architectures. Co-founder in 2004 of Nohup, a digital consultancy in cloud-native development, he led the company to Financial Times recognition among Europe's leading firms in the sector for two consecutive years (2021 and 2022). In August 2021 Nohup was acquired by the Havas Group, bringing its 30 professionals across Milan, Turin, and Udine into Havas CX. The distinctive trait of Fabbri's path is engineering rigor, attention to privacy, and deep knowledge of media operational workflows — an essential asset within the European framework of AI Act, GDPR, and the Italian Consumer Code.

The AI-driven leap for SMEs and Agencies

Under Fabbri's leadership, Audiencerate will accelerate on two parallel tracks. On the SME front, AI and machine learning enable continuous model learning, predictive modeling (propensity scoring, lookalike, CLV) and self-optimization of budget and bid management. On the agency front, advertisers' first-party data serves as seed for lookalike and propensity models enriched with third-party signals: an audience that combines 1P relevance with 3P scale, compliant with privacy and cookie ecosystem evolution.

Statements

"Riccardo's entry is the missing piece," said Gianluca Leotta, President of Audiencerate. "A technologist-entrepreneur who took Nohup to a European exit, lived inside the international media agency world, and knows the technical grammar of our trajectory exactly. It is a long-term choice, consistent with the patrimonial and industrial vision we have always had for this project."

"Audiencerate has built over the years a unique technological asset: a Data Provider position native to both Google and Microsoft ecosystems, with certifications and partnerships that very few companies can claim," said Riccardo Fabbri. "The project is both challenging and exciting. On one side, bringing this infrastructure to millions of Italian SMEs through Postel and Microsoft. On the other, evolving the DV360 offering by drawing on twenty years alongside media agencies: trading desks need models that intelligently fuse first-party and third-party data, while pursuing the automation and scale needed to recover margins the market no longer recognizes as it once did. This is the kind of engineering challenge that resonates with my path as a founder and entrepreneur."

About Audiencerate

Audiencerate Ltd, headquartered in London with offices in Italy and the United States, specializes in data activation, audience intelligence, and AI-driven marketing. Google Customer Match Upload Partner (December 2025), Google Data Provider since 2012, Microsoft IP Co-sell Eligible / MACC Eligible. NEXI is the company's flagship enterprise client in Italy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519344995/en/

Contacts

Media contact:
press@audiencerate.com · www.audiencerate.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.audiencerat
e.com&esheet=54538884&newsitemid=20260519344995&lan=en-US&anchor=www.audiencerat
e.com&index=1&md5=2b49e74d6b03c34c97c4b13436db6ae3

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye